[(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester | 1262803-67-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester
• 英文别名: [(3S,4S,5R)-3-(2-Fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butyl ester；tert-butyl N-[(3S,4S,5R)-3-(2-fluorophenyl)-4-formyl-5-methyloxolan-3-yl]carbamate
• CAS: 1262803-67-7
• 化学式: C₁₇H₂₂FNO₄
• 分子量: 323.364
• InChiKey: WDLLEDIPYRBAQW-CJBNDPTMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester 、 (三氟甲基)三甲基硅烷 在 四丁基氟化铵 作用下， 反应 2.0h， 生成 [(3S,4R,5R)-3-(2-fluoro-phenyl)-5-methyl-4-(2,2,2-trifluoro-1-hydroxy-ethyl)-tetrahydro-furan-3-yl]-carbamic acid tert-butyl ester 、 tert-butyl N-[(3S,4R,5R)-3-(2-fluorophenyl)-5-methyl-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]oxolan-3-yl]carbamate
  参考文献：
  名称：

  [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES
  [FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE

  摘要：

  通用式（I）或其药用可接受盐或其溶剂的化合物，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。

  公开号：

  WO2011009898A1
• 作为产物：
  描述：

  tert-butyl ((3S,4R,5R)-3-(2-fluorophenyl)-4-(hydroxymethyl)-5-methyltetrahydrofuran-3-yl)carbamate 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到[(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester
  参考文献：
  名称：

  [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES
  [FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE

  摘要：

  通用式（I）或其药用可接受盐或其溶剂的化合物，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。

  公开号：

  WO2011009898A1
• 作为试剂：
  描述：

  tert-butyl ((3S,4R,5R)-3-(2-fluorophenyl)-4-(hydroxymethyl)-5-methyltetrahydrofuran-3-yl)carbamate 、 、 ethyl acetate n-hexane 、 碳酸氢钠 、 sodium hydrogensulfite 在 1,1,1-tris(acetyloxy) 、 [(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester 、 magnesium sulfate 、 ethyl acetate n-hexane 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以900 mg of the title compound was isolated (76% yield)的产率得到[(3S,4R,5R)-3-(2-fluoro-phenyl)-4-formyl-5-methyl-tetrahydro-furan-3-yl]-carbamic acid tert-butylester
  参考文献：
  名称：

  FUSED AMINODIHYDRO-OXAZINE DERIVATIVES

  摘要：

  化合物由通式（I）或其药学上可接受的盐或溶剂化物表示，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物。该化合物具有Aβ产生抑制作用或BACE1抑制作用，并且可用作预防或治疗由Aβ引起的、以阿尔茨海默型痴呆为代表的神经退行性疾病的药物。

  公开号：

  US20120202804A1

文献信息

• Fused aminodihydro-oxazine derivatives
  申请人：Ellard John Mark

  公开号：US09079914B2

  公开（公告）日：2015-07-14

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一种化合物，其一般式表示为：或其药学上可接受的盐或溶剂，其中环A是C6-14芳基或类似物，L为-NReCO-或类似物（其中Re为氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地为氢原子或类似物，而R3、R4、R5和R6各自独立地为氢原子、卤原子或类似物。该化合物具有抑制Aβ产生或抑制BACE1的作用，并可用作预防或治疗由Aβ引起的神经退行性疾病，如阿尔茨海默病的药物。
• Fused Aminodihydro-Oxazine Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2653473A1

  公开（公告）日：2013-10-23

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  由通式表示的化合物： 或其药学上可接受的盐或其溶液，其中环 A 是 C6-14 芳基或类似物，L 是 -NReCO- 或类似物（其中 Re 是氢原子或类似物），环 B 是 C6-14 芳基或类似物，X 是 C1-3 亚烷基或类似物，Y 是单键或类似物，Z 是 C1-3 亚烷基或类似物、R1和R2各自独立地为氢原子或类似物，R3、R4、R5和R6各自独立地为氢原子、卤素原子或类似物，具有抑制Aβ生成的作用或抑制BACE1的作用，可作为由Aβ引起的、以阿尔茨海默型痴呆为典型的神经退行性疾病的预防剂或治疗剂。
• 4,4a,5,7-TETRAHYDRO-3H-FURO[3,4-b]PYRIDINYL COMPOUNDS
  申请人：Janssen Pharmaceutlca NV

  公开号：US20200062773A1

  公开（公告）日：2020-02-27

  The present invention relates to 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compound inhibitors of beta-site APP-cleaving enzyme having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-site APP-cleaving enzyme is involved, such as Alzheimer's disease (AD), mild cognitive impairment, preclinical Alzheimer's disease, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, and dementia associated with beta-amyloid.
• US9079914B2
  申请人：——

  公开号：US9079914B2

  公开（公告）日：2015-07-14
• [EN] FUSED AMINODIHYDRO-OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS CONDENSÉS D'AMINODIHYDRO-OXAZINE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2011009898A1

  公开（公告）日：2011-01-27

  A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  通用式（I）或其药用可接受盐或其溶剂的化合物，其中环A是C6-14芳基或类似物，L是-NReCO-或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基或类似物，Y是单键或类似物，Z是C1-3烷基或类似物，R1和R2各自独立地是氢原子或类似物，R3、R4、R5和R6各自独立地是氢原子、卤素原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。